Association of A313G glutathione S-transferase P1 germline polymorphism with susceptibility to de novo myelodysplastic syndrome. Issue 8 (August 2013)

• Record Type: Journal Article
• Authors: Zachaki, Sophia; Stavropoulou, Chrysa; Kalomoiraki, Marina; Koromila, Theodora; Daraki, Aggeliki; Manola, Kalliopi N.; Mavrou, Ariadni; Kanavakis, Emmanuel; Pantelias, Gabriel E.; Sambani, Constantina
• Is Part Of: Leukemia & lymphoma. Volume 54:Issue 8(2013:Aug.)
• Page Start: 1756
• Page End: 1761
• Publication Date: 2013-08
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2012.762647
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>Models for the pathogenesis of myelodysplastic syndrome (MDS) imply the role of individual genetic variations in genes involved in detoxification mechanisms. GSTP1 enzyme plays a key role in the biotransformation of a variety of carcinogens. The corresponding gene is subject to a single nucleotide polymorphism (A³¹³G) leading to abolished enzyme activity. In order to evaluate whether the <italic>GSTP1</italic> polymorphism influences MDS susceptibility, we conducted a case–control study comprising 310 <italic>de novo</italic> patients and 370 healthy controls using a real-time polymerase chain reaction (PCR) genotyping method. The <italic>GSTP1</italic> gene status was also evaluated in relation to patients' characteristics and chromosomal abnormalities. A significantly higher incidence of the <italic>GSTP1</italic> variant genotypes was observed in patients with MDS compared to controls (<italic>p</italic> &lt; 0.0001). The results revealed increased frequencies of heterozygotes in patients younger than 60 years old and of homozygotes G/G in older patients (<italic>p</italic> = 0.007). Our results provide evidence for a pathogenetic role of the <italic>GSTP1</italic> polymorphism in MDS risk, probably in an age-dependent manner.</p> </abstract>